Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jessica Merrill

Senior Editor

New York, NY
Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest From Jessica Merrill

Blueprint’s Evolution On Its Path To Financial Sustainability

Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.

Launches Business Strategies

Jardiance Improves Double-Digit Growth Potential With US Approval In CKD

Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.

Approvals Launches

Administrative Burden, Class-Wide Impacts Are Among IRA Pitfalls

As Medicare drug price negotiations creep closer to reality, industry leaders are turning attention to the challenges of implementation and commercial concerns.

Pricing Debate Politics

BioMarin’s Next Chapter: ‘A Financial Growth Story’

The company presented its pipeline to investors during an R&D day, outlining expansion plans for Voxzogo and Roctavian as well as several early pipeline drugs.

Rare Diseases Research & Development

Amgen’s Plan To Go Big In Obesity

Competing in the obesity market will require significant investment, which Amgen is preparing for, CEO Robert Bradway told investors during the Morgan Stanley Healthcare conference.

Metabolic Disorders Research & Development

Seagen And Nurix Hope To Pioneer A New Class Of Degrader-Antibody Conjugates

The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.

Deals Platform Technologies
See All
UsernamePublicRestriction

Register